- Published at
- by marketscreener.com
neutral
neutral
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
Nes Ziona, Israel, Feb. 12, 2021 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis,... | February 12, 2021